Abstract

Stevanato Group S.p.A. will release its quarterly results on May 7, 2026 Pre-Market, with consensus expecting year-over-year revenue growth and improving profitability; investors will focus on whether the company’s guidance cadence and mix shift support sustained EPS acceleration through the year.

Market Forecast

Consensus for the current quarter points to revenue of 269.35 million euros, up 8.91% year over year, EBIT of 39.13 million euros, up 18.22% year over year, and adjusted EPS of 0.10 euros, up 15.49% year over year. Management’s full-year 2026 outlook communicated in the prior update implied a balanced growth path for the year; against that backdrop, the current quarter’s estimates suggest a typical seasonal step-down from the prior quarter while maintaining year-over-year expansion.

The company’s core portfolio is expected to continue benefiting from mix improvements and disciplined execution, with the topline anchored by the main solutions franchise and supported by steady project activity. The most promising segment remains the biopharmaceutical and diagnostic solutions franchise, which drove approximately 303.00 million euros of last quarter’s revenue; the group-level year-over-year revenue growth was 4.81%, and investors will watch for a similar or better trend as the year unfolds.

Last Quarter Review

In the previous quarter, Stevanato Group S.p.A. reported revenue of 346.50 million euros, a gross profit margin of 31.38%, GAAP net profit attributable to the parent company of 47.56 million euros, a net profit margin of 13.72%, and adjusted EPS of 0.18 euros; revenue rose 4.81% year over year while adjusted EPS declined 5.26% year over year, and net profit increased 31.86% sequentially. The company outperformed external expectations, with revenue exceeding the prior estimate by 13.49 million euros and adjusted EPS surpassing the estimate by 0.01 euros, reflecting resilient demand and firm cost control exiting the year.

Within the quarter, the biopharmaceutical and diagnostic solutions franchise was the key revenue engine at approximately 303.00 million euros, while engineering support contributed around 82.08 million euros; the overall business advanced 4.81% year over year, demonstrating sustained momentum despite a high comparison base.

Current Quarter Outlook

Main operations and near-term execution

The current quarter’s revenue estimate of 269.35 million euros implies a sequential step-down from the prior quarter’s 346.50 million euros, a pattern consistent with typical first-quarter seasonality for the company, while still delivering an 8.91% year-over-year increase. This level of growth, paired with a forecasted 15.49% rise in adjusted EPS to 0.10 euros and an 18.22% increase in EBIT to 39.13 million euros, frames a narrative of incremental margin recovery driven by mix, scale, and operating discipline. The combination of mid-to-high single-digit sales growth with a faster increase in EBIT suggests the company is positioned to extract operating leverage, even as volumes normalize from the stronger year-end close.

Given last quarter’s gross margin of 31.38% and net margin of 13.72%, the market will gauge whether pricing, product mix, and cost execution can support stable-to-better conversion of revenue to profit in the current period. The 31.86% sequential increase in net profit last quarter underscored exiting-quarter strength, and the path into the current quarter will hinge on sustaining throughput in higher-value offerings and efficiently scheduling engineering-related project work. Investors should also consider currency as an optical factor; the company reports in euros, and fluctuations during the quarter can influence reported results and comparability without altering underlying demand.

Most promising franchise and mix implications

The biopharmaceutical and diagnostic solutions franchise remains the bedrock of performance, contributing roughly 303.00 million euros last quarter and underlining the company’s capacity to support critical solutions across its customer base. This franchise tends to carry a richer margin profile than project-oriented revenue streams, and its continued expansion is central to the expected 15.49% increase in adjusted EPS despite mid-to-high single-digit sales growth. As the business continues to favor higher-value formats and product configurations within this franchise, the earnings algorithm can benefit from a favorable mix shift, even when sequential revenue moderates from year-end levels.

In the current quarter, investors will look for confirmation that this franchise is converting backlog and demand signals into steady shipments, as indicated by the year-over-year revenue estimate of 269.35 million euros. The franchise’s revenue contribution last quarter provides a basis to track quarterly cadence: if this mix remains solid, it can underpin EBIT growth of 18.22% year over year, in line with consensus. Any commentary around backlog visibility, customer rollout timing, and product format mix will be pivotal for anticipating the pace of margin expansion over the subsequent quarters of 2026.

Key stock-price drivers this quarter

Three items are likely to have the greatest impact on the stock around the print. First, the alignment of revenue and EPS with consensus and whether management reiterates or refines its full-year 2026 construct will shape the near-term trajectory; meeting or modestly exceeding the current quarter on both the top and bottom lines while affirming the annual path would validate the earnings ramp implied by the estimates. Second, the margin profile is under watch: with revenue guided by consensus to rise 8.91% year over year and EBIT to rise 18.22% year over year, investors will scrutinize gross-to-operating margin translation to ensure operating leverage is materializing as expected. Third, order cadence and project timing inside engineering support can produce quarter-to-quarter variability; consistent scheduling and execution help smooth revenue recognition and protect the earnings cadence assumed by the Street.

Beyond the quarter, expectations embedded in the full-year outlook provide an anchor for valuation and revisions. The prior communication of a 2026 revenue range suggests confidence in pipeline conversion, yet quarter-level delivery remains the gating factor for estimate moves. Should the company pair in-line revenue with better-than-expected profitability—through mix benefits and cost execution—positive revisions could follow; conversely, any slippage in margin capture or commentary that points to elongated project timelines would be a headwind for near-term sentiment.

Analyst Opinions

Across the period reviewed, the balance of published views skews bullish, with a 100% to 0% ratio of bullish to bearish opinions among the items captured. William Blair, through analyst Matt Larew, reiterated a Buy rating during the period, reflecting confidence in the company’s ability to execute against 2026 targets and the near-term setup for the quarter. Market participants also noted that the last reported quarter exceeded revenue and adjusted EPS expectations and that the company introduced a measured full-year 2026 outlook, which together frame a supportive backdrop for this quarter’s report.

The majority viewpoint emphasizes that the current-quarter model—269.35 million euros in revenue, 39.13 million euros in EBIT, and 0.10 euros in adjusted EPS—appears achievable given the strong exit from the prior year and the mix tilt toward higher-value offerings. This perspective also underlines that the implied margin progression (EBIT up 18.22% year over year versus revenue up 8.91%) aligns with the company’s focus on profitability in addition to growth, a combination that can sustain earnings momentum through the year if execution remains consistent. In this construct, potential upside would be driven by faster conversion in the core franchise, disciplined cost control, and confirmation that the annual framework remains intact after the first-quarter checkpoint.

From a sentiment standpoint, this bullish stance reflects confidence that the quarter will reinforce the company’s earnings cadence rather than reset it. The narrative is not predicated on outsize surprises; rather, it hinges on steady delivery against consensus, incremental improvements in profitability, and a clean translation from backlog and project pipeline into recognized revenue. Confirmation of these points would validate management’s trajectory communicated earlier in the year and could support continued constructive views on the stock as 2026 progresses.